Shanghai Allist Pharma’s Phase‑III Failure Sparks Investor Alarm, Call for Diversification
Allist Pharma faces a crisis after its flagship drug Furvent fails Phase III, leaving investors wary and the company’s future in doubt.
3 minutes to read
SHANGHAI ALLIST PHARMACEUT